Nicotine Reinforcement & Aversion in Young Adult Light Smokers

Status Completed

Clinical Trial Summary

The proposed study will examine the threshold for nicotine self-administration (NSA) using five different nicotine doses in young adult male and female non-dependent smokers (light and intermittent smokers or LITS). We propose a double-blind, placebo-controlled study that will enroll 195 individuals, targeting a total of 72 completers (36 male and 36 females). In each of the five experimental sessions, smokers will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.05, 0.1 and 0.2 mg/70 kg). The highest dose, 0.2 mg/70 kg, corresponds to nicotine delivered by about one or two puffs of a cigarette. At the beginning of each experimental session, smokers will sample the assigned both the nicotine dose for that experimental session, and the placebo (saline) dose, followed by the opportunity to choose between nicotine and placebo for a total of ten choices over a 150-minute period. The main outcomes will be threshold dose (the minimum dose of nicotine that is self-administered more than placebo) and the slope of dose-response for nicotine self-administration (changes in nicotine self-administration per unit change in nicotine dose). We will also collect measures of nicotine intake (cotinine), nicotine clearance (3-hydroxycotinine (3-HC) / cotinine), and self-report drug effects

Clinical Trial Description

Aim #1: To assess the threshold reinforcing dose and dose-effect curve for IV NSA at low doses in young adult LITS. Hypothesis #1A: The threshold reinforcing doses for IV NSA will be between 0.0125 to 0.1 mg/70 kg. Hypothesis #1B: The dose-effect curve for NSA will differ between males and females with relatively flat curve in female smokers. Aim #2: To assess the threshold and dose-effect curve for the positive and negative/aversive subjective effects of IV nicotine at low doses and its relationship to nicotine reinforcement. Hypothesis #2 A: The threshold for the positive effects will be between 0.0125 to 0.1 mg/70 kg, for the negative/aversive effect it will be ≥ 0.1 mg/70 kg. Hypothesis #2B: Nicotine reinforcement will be positively correlated with the positive and negatively correlated with the negative/aversive subjective effects of IV nicotine. Exploratory Aims: To examine the influence of nicotine clearance rate on nicotine reinforcement threshold and dose-effect curve. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01495819
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Early Phase 1
Start date	January 4, 2017
Completion date	March 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Completed	`NCT02153749` - Effects of Brief Training on Craving Regulation	N/A
Recruiting	`NCT05530577` - Effects of Semaglutide on Nicotine Intake	Phase 2
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT01944423` - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine	Early Phase 1
Completed	`NCT01704573` - Nicotinic Receptor Levels After Stopping Smoking	N/A
Active, not recruiting	`NCT01015170` - STOP Study: Effectiveness of Zyban in a Clinical Population	Phase 4
Completed	`NCT03281629` - Circuitry-Guided Smoking Cessation in Schizophrenia	N/A
Recruiting	`NCT06291584` - Effects of Exercises on Functional Capacity	N/A
Withdrawn	`NCT06259630` - Nicotine Virtual Reality Conditioned Place Preference	Phase 4
Completed	`NCT02624284` - tDCS Effects on Resisting Smoking: Dose Ranging Study	N/A
Active, not recruiting	`NCT02837510` - Neural Mechanisms Associated With Risk of Smoking Relapse	N/A
Completed	`NCT02656745` - Clinical Trial of Smoking Cessation Mobile Phone Program	N/A
Completed	`NCT01062932` - Investigation of Cycloserine as a Smoking Cessation Treatment	Phase 1
Completed	`NCT03069482` - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness	Phase 1
Completed	`NCT02870218` - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use	Phase 2
Terminated	`NCT01756053` - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward	Phase 2
Completed	`NCT01252966` - Cognitive Training for Nicotine Dependence	N/A
Active, not recruiting	`NCT04946825` - Quit Smoking Study for People Who Use E-Cigarettes	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Nicotine Reinforcement and Aversion in Young Adult Light Smokers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms